What is Leerink Partnrs’ Estimate for BBIO FY2027 Earnings?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Leerink Partnrs reduced their FY2027 EPS estimates for BridgeBio Pharma in a research note issued on Sunday, November 24th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of $1.30 for the year, down from their prior estimate of $1.31. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.56) per share.

A number of other analysts also recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $70.00 target price on shares of BridgeBio Pharma in a report on Monday, September 16th. Leerink Partners reduced their price objective on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Scotiabank raised their price objective on BridgeBio Pharma from $45.00 to $48.00 and gave the company a “sector outperform” rating in a research note on Monday. Bank of America lifted their target price on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday. Finally, Evercore ISI decreased their price target on BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, BridgeBio Pharma has an average rating of “Moderate Buy” and a consensus price target of $48.43.

BridgeBio Pharma Stock Up 4.0 %

BridgeBio Pharma stock opened at $27.49 on Tuesday. BridgeBio Pharma has a 52-week low of $21.62 and a 52-week high of $44.32. The firm’s fifty day moving average is $25.00 and its 200 day moving average is $26.22. The company has a market cap of $5.20 billion, a price-to-earnings ratio of -11.41 and a beta of 1.09.

Hedge Funds Weigh In On BridgeBio Pharma

Several institutional investors have recently bought and sold shares of BBIO. Price T Rowe Associates Inc. MD grew its position in shares of BridgeBio Pharma by 22.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 803,956 shares of the company’s stock worth $24,859,000 after buying an additional 145,594 shares during the last quarter. First Turn Management LLC purchased a new position in BridgeBio Pharma in the third quarter worth $10,178,000. Jennison Associates LLC acquired a new position in BridgeBio Pharma during the 3rd quarter valued at about $767,000. Comerica Bank raised its stake in BridgeBio Pharma by 3,013.5% in the first quarter. Comerica Bank now owns 38,514 shares of the company’s stock valued at $1,191,000 after buying an additional 37,277 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. raised its stake in BridgeBio Pharma by 6.4% in the second quarter. Frazier Life Sciences Management L.P. now owns 3,632,604 shares of the company’s stock valued at $92,014,000 after buying an additional 217,000 shares during the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 4,156 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $93,135.96. Following the transaction, the chief financial officer now owns 93,758 shares in the company, valued at approximately $2,101,116.78. This trade represents a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the completion of the sale, the insider now owns 25,260,971 shares of the company’s stock, valued at approximately $650,470,003.25. This represents a 18.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,831,545 shares of company stock valued at $150,056,923 in the last three months. Company insiders own 24.66% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.